Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PTPRB | P23467 | 5/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PTPRA | P18433 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826617 | 0.84 | FFAR1 (0.35) | FFAR1CA1CA2POLB | |
| SCHEMBL25827939 | 0.82 | ESR1 (0.40) | ESR1THRATHRBRAB9AALDH1A1 | |
| SCHEMBL25826613 | 0.78 | ESR1 (0.37) | FFAR1ESR1THRATHRB | |
| SCHEMBL25827946 | 0.70 | HRH3 (0.43) | ESR1THRATHRB | |
| SCHEMBL25826622 | 0.69 | ESR1 (0.38) | FFAR1CA1CA2ESR1THRA | |
| SCHEMBL15242395 | 0.68 | ALDH1A1 (0.43) | CA1CA2HPGDNPC1RAB9A | |
| SCHEMBL25826615 | 0.68 | SMN1; SMN2 (0.38) | FFAR1PTPN1 | |
| SCHEMBL15183846 | 0.64 | HRH3 (0.33) | ALDH1A1 | |
| SCHEMBL13668105 | 0.64 | SMN1; SMN2 (0.56) | ESR1THRATHRBHPGDNPC1 | |
| SCHEMBL25827940 | 0.63 | CES2 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | GLUL, TGM2, GLS | FFAR1 3820/4885CA1 1359/4885CA2 2515/4885 |
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | FFAR1 3820/4885CA1 1359/4885CA2 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.